Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 15.1% Today

What is Aurora Cannabis Inc.?

Aurora Cannabis (ACB) is a leading Canadian company in the medical cannabis industry, known for its innovative products and international market presence.

Why is Aurora Cannabis Inc. going up?

ACB stock is up 15.1% on Dec 12, 2025 16:35

• ACB stock experienced a strong bullish movement today, rallying approximately 15% in pre-market trading.
• The surge was fueled by considerations around the reclassification of marijuana as a Schedule III drug, potentially easing penalties and tax burdens for cannabis companies.
• The launch of a new high-potency medical cannabis product, Black Jelly, in Poland also contributed to the positive market sentiment and reinforced Aurora's leadership in the international medical cannabis market.
• Despite facing financial challenges and bankruptcy risks, Aurora's strategic expansions and product innovations continue to attract investors and drive the stock price higher.

ACB Price Chart

ACB Technical Analysis

ACB News

Aurora Cannabis (ACB) Stock Jumps on US Marijuana Rescheduling Headlines: Today's News, Forecasts, and Analysis (Dec. 12, 2025)

Aurora Cannabis (ACB) stock rallied approximately 15% in pre-market trading on December 12, 2025, driven by reports that President Donald Trump is considering reclassifying marijuana as a Schedule III drug. This potential federal policy shift is expected to ease criminal penalties, reduce tax burdens for cannabis companies by exempting them from IRS Section 280E, and improve access to financing. While Aurora is a Canada-based company, the news created a strong sector-wide repricing effect and positively impacted investor sentiment regarding future strategic flexibility in the US market, despite an important caveat from the White House that no final decisions have been made.

https://ts2.tech/en/aurora-cannabis-acb-stock-jumps-on-us-marijuana-rescheduling-headlines-todays-news-forecasts-and-analysis-dec-12-2025/

Aurora Cannabis Inc. (ACB:CA) ATB Capital Cuts Target on Market Volatility

ATB Capital has reduced its 12-month target price for Aurora Cannabis Inc. (ACB:CA) to $8.50 from $9.00, citing cannabis sector volatility and slower-than-expected market normalization. Despite the cut, ATB maintains an "Outperform" rating, expressing confidence in Aurora's long-term strategy, profitability focus, operational streamlining, and leadership in the global medical cannabis market. The revised target reflects industry-wide pressures rather than specific weakening fundamentals of Aurora.

https://www.theglobeandmail.com/investing/markets/stocks/ACB/pressreleases/36586398/aurora-cannabis-inc-acbca-atb-capital-cuts-target-on-market-volatility/

Aurora Expands Leading Portfolio of High-Potency Medical Flower Products in Poland

Aurora Cannabis Inc. has launched Black Jelly, a new high-potency proprietary cannabis cultivar, in Poland, expanding its medical cannabis offerings in one of Europe's fastest-growing markets. This new product, grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities, features 27% THC and is derived from Alien Cake 3030 × T037 genetics. The expansion reinforces Aurora's leadership in international medical cannabis through its genetic breeding program and cultivation excellence.

https://www.cannabisbusinesstimes.com/international/news/15773968/aurora-expands-leading-portfolio-of-highpotency-medical-flower-products-in-poland

Aurora Cannabis (NASDAQ: ACB) debuts high-THC Black Jelly medical flower in Poland

Aurora Cannabis (NASDAQ: ACB) has launched Black Jelly, a high-THC medical cannabis cultivar, in Poland, expanding its portfolio of high-potency products in one of Europe's fastest-growing markets. Black Jelly, with a cannabinoid profile of THC 27% / CBD <1%, is grown in Aurora's Canadian GACP and EU-GMP certified facilities and is available for Polish prescribers immediately. This move strengthens Aurora's leadership in international medical cannabis markets.

https://www.stocktitan.net/news/ACB/aurora-expands-leading-portfolio-of-high-potency-medical-flower-r0ine1jxct1q.html

Aurora Cannabis (ACB) Expands Medical Portfolio with Black Jelly Launch in Poland

Aurora Cannabis (ACB) has launched its new medical cannabis product, Black Jelly, in the Polish market, aiming to meet the demand for high-quality medical cannabis through its advanced genetic breeding and cultivation expertise. Despite this strategic expansion and strong liquidity, the company faces significant financial challenges, including negative revenue growth and net margin, and an Altman Z-Score indicating potential bankruptcy risk, urging investor caution.

https://www.gurufocus.com/news/3244781/aurora-cannabis-acb-expands-medical-portfolio-with-black-jelly-launch-in-poland

Trending Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.1% Today

Cronos Group Inc. ($CRON) Stock Forecast: Down 5.0% Today

Chainlink ($LINK) Crypto Forecast: Down 5.6% Today

Roper Technologies Inc. ($ROP) Stock Forecast: Down 0.8% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.1% Today

BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Down 2.1% Today

CoStar Group Inc. ($CSGP) Stock Forecast: Down 5.2% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 1.4% Today

Binance Coin ($BNB) Crypto Forecast: Down 3.4% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Down 5.1% Today

Aurora Cannabis Inc. Price History

18.05.2025 - ACB Stock was down 22.7%

• The decline in ACB stock is linked to lower-than-expected demand in the global market, evident from the Q4 earnings missing estimates.
• Despite improved adjusted EBITDA and global medical cannabis net revenue, the market reacted negatively due to reported quarterly loss per share.
• The stock fall during pre-market trading, dropping by 20.1% post fourth-quarter results, added to the negative sentiment surrounding ACB.
• Concerns about future growth and operational efficiency are likely driving investor worries, contributing to the downward trend in ACB stock.

04.05.2025 - ACB Stock was up 5.3%

• Recommendation by a notable financial commentator favoring Nvidia over Aurora Cannabis potentially influenced investors to shift focus towards the semiconductor industry, positively impacting ACB's stock.
• The upward trend in ACB's stock value could also be linked to investors seeking growth prospects in the cannabis sector amid evolving regulations and growing market demand.
• The optimistic outlook on ACB may be fueled by market participants anticipating robust financial performance or strategic partnerships in the future, leading to an increase in the stock price.

29.08.2025 - ACB Stock was up 6.0%

• The implied volatility surging for Aurora Cannabis stock options indicates a heightened interest and activity in the options market, potentially leading to increased buying pressure on the stock.
• This surge in implied volatility could suggest that investors are anticipating significant price movements in ACB stock, leading to a bullish momentum in the market.
• The increased attention from investors in the options market may be driven by positive news or developments surrounding Aurora Cannabis, contributing to the strong bullish movement observed in the stock today.

29.08.2025 - ACB Stock was up 4.4%

• There was a notable bullish movement in the stock of ACB today.
• Positive sentiment within the cannabis industry was sparked by President Trump's public endorsement of the potential health benefits of cannabis on social media.
• Increased interest from investors and potential speculation on future price changes is reflected in the surge of implied volatility for ACB stock options.
• The surge in ACB stock price was likely influenced by a combination of Trump's supportive stance on cannabis and the heightened activity in options trading.

20.02.2025 - ACB Stock was up 6.0%

• The bullish movement in ACB's stock today is possibly linked to the favorable sentiment surrounding the global legalization of cannabis, positioning the company well to benefit from this trend.
• A comparison with Concentra Group suggests that ACB is excelling within the medical stocks sector, potentially enhancing investor confidence in the stock.
• ACB's extensive regulatory expertise and robust manufacturing capabilities likely played a part in its strong performance, attracting investors interested in the expanding medical cannabis market.

20.02.2025 - ACB Stock was up 7.5%

• ACB's bullish movement today can be attributed to the discovery of a new source of genetic resistance against powdery mildew in cannabis sativa, showcasing the company's commitment to innovation and product development.
• The company's strategic positioning in the rapidly evolving medical cannabis landscape, with EU GMP-certified manufacturing facilities and advanced genetics, has also contributed to investor confidence and interest in ACB.
• As the global legalization wave for cannabis continues to gain momentum, ACB's strong performance and focus on developing powdery mildew-resistant plants further solidify its position as a key player in the industry, attracting potential investors seeking growth opportunities in the sector.

06.07.2025 - ACB Stock was down 5.6%

• The bearish movement in ACB today could be attributed to the near-term regulatory headwinds mentioned in the pre-Q1 earnings analysis, which may have limited revenue upside for the company.
• Options market movements might indicate that traders are anticipating further downside in ACB stock, leading to increased selling pressure.
• Investors are likely cautious about the regulatory challenges and potential revenue constraints facing Aurora Cannabis, prompting them to consider selling or holding their positions rather than buying more shares at the moment.

06.07.2025 - ACB Stock was down 7.5%

• Despite surpassing revenue estimates, Aurora Cannabis Inc. (ACB) reported a significant loss in Q1, leading to a decline in the stock price.
• The company's strong global medical cannabis momentum was impacted by short-term regulatory obstacles, affecting its revenue performance in the quarter.
• Market options indicate that investors are attentively watching ACB stock, reflecting possible uncertainty and caution regarding the company's future.
• The combination of underwhelming financial results and regulatory hurdles likely contributed to the bearish market movement of Aurora Cannabis Inc. (ACB) today.

12.11.2025 - ACB Stock was up 10.1%

• The increase in ACB stock value today is linked to the company's strategic expansion of its medical cannabis portfolio through the introduction of Black Jelly in Poland, allowing access to one of Europe's fastest-growing markets.
• The launch of a new proprietary high-potency medical cannabis strain, with a THC content of 27% and cultivated in Aurora's advanced facilities, highlights the company's dedication to meeting the demand for premium medical cannabis products.
• Despite financial difficulties and concerns about potential bankruptcy, the favorable market reception to Aurora's product expansion demonstrates investor confidence in the company's capability to capitalize on its expertise in global markets and effectively address patient and prescriber requirements.

12.11.2025 - ACB Stock was up 15.1%

• ACB stock experienced a strong bullish movement today, rallying approximately 15% in pre-market trading.
• The surge was fueled by considerations around the reclassification of marijuana as a Schedule III drug, potentially easing penalties and tax burdens for cannabis companies.
• The launch of a new high-potency medical cannabis product, Black Jelly, in Poland also contributed to the positive market sentiment and reinforced Aurora's leadership in the international medical cannabis market.
• Despite facing financial challenges and bankruptcy risks, Aurora's strategic expansions and product innovations continue to attract investors and drive the stock price higher.

08.07.2025 - ACB Stock was up 5.1%

• ACB stock experienced a strong bullish movement despite Q1 earnings missing estimates, showcasing resilience in the face of challenges.
• The 17.5% year-over-year revenue growth indicates the company's ability to capitalize on the strong global medical cannabis demand.
• Investors seem optimistic about ACB's future potential, as the stock beat revenue estimates despite reporting a loss, hinting at long-term growth prospects.
• Despite near-term regulatory headwinds impacting Q1 revenue, ACB's solid global medical cannabis momentum suggests a promising outlook for the stock.

18.05.2025 - ACB Stock was down 19.3%

• ACB stock experienced a significant bearish movement of 20.1% in pre-market trading.
• The fourth-quarter results of Aurora Cannabis showed a quarterly loss of 24 cents per share, which disappointed investors.
• The negative earnings report likely contributed to the sharp decline in ACB stock price as investors reacted to the company's financial performance.
• The overall bearish sentiment in the market could have also played a role in the downward movement of ACB stock.